### Guideline Page and Request

VULVA-D
Institutional Review Request:
Consider revising the pembrolizumab second-line systemic therapy option to include the PD-L1-positive indication.

### Panel Discussion/References

Based upon review of data extrapolated from the noted cervical cancer reference(s), the panel consensus was to expand the use of pembrolizumab to include PD-L1-positive tumors. As a result, the second-line therapy option for advanced, recurrent/metastatic disease changed from "Pembrolizumab for MSI-H/dMMR tumors (category 2B)" to "Pembrolizumab for PD-L1-positive or MSI-H/dMMR tumors (category 2A)"


### Institution Vote

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>2</td>
<td>2</td>
<td>4</td>
</tr>
</tbody>
</table>